Plain-English translation of NCT06124612 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atrial Fibrillation research guide →This trial is studying whether asundexian, a newer type of blood thinner, helps your body dissolve blood clots better than apixaban, a more commonly used blood thinner. Right now, doctors can thin your blood with medications, but they haven't had good ways to measure whether these drugs help your body's natural ability to break down clots. This study uses extra blood tests from people already taking part in a larger trial to answer that important question.
People with atrial fibrillation have a higher risk of dangerous blood clots that can cause heart attacks and strokes. While current blood thinners work by making blood less sticky, they don't always improve your body's natural clot-dissolving defenses—which research now shows are just as important. This medication is being tested to see if it works better at activating those natural defenses.
You likely qualify if…
You likely don't qualify if…
You will continue taking whichever medication you were assigned in the main OCEANIC-AF study (either asundexian or apixaban). The only additional requirement is that researchers will draw extra blood samples from you at certain visits to run special tests that measure how well your body can dissolve clots. The study takes place at two centers in England and involves no extra visits beyond what you're already doing for the main trial.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United Kingdom